Altered Structural Brain Networks Related to Adrenergic/Muscarinic Receptor Autoantibodies in Chronic Fatigue Syndrome.
Fujii, Hiroyuki, Sato, Wakiro, Kimura, Yukio et al. · Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2020 · DOI
Quick Summary
This study looked at whether certain antibodies in the blood (proteins that attack the body's own receptors) are connected to changes in brain structure in ME/CFS patients. Researchers scanned the brains of 89 ME/CFS patients and measured levels of four specific autoantibodies, then looked for patterns. They found that two of these autoantibodies showed a relationship with how brain networks are organized in specific areas, suggesting these antibodies might be useful markers for identifying ME/CFS.
Why It Matters
This research provides evidence that autoantibodies against adrenergic and muscarinic receptors—which may dysfunction the autonomic nervous system—correlate with specific structural changes in ME/CFS brain networks. If validated, these antibodies could become objective biomarkers to help diagnose ME/CFS and understand the biological mechanisms underlying the disease.
Observed Findings
β1-adrenergic receptor autoantibodies positively correlated with betweenness centrality (a measure of network connectivity) in the right dorsolateral prefrontal cortex.
β2-adrenergic receptor autoantibodies negatively correlated with characteristic path length in the right precentral gyrus.
No significant correlations were found between autoantibody titers and regional gray matter or white matter volumes.
No significant correlations were found between autoantibody titers and global network properties (small-world network measures).
Inferred Conclusions
β1 and β2 adrenergic receptor autoantibodies are potential biomarkers for ME/CFS.
Autoantibodies may influence local brain network organization in specific regions related to motor control and executive function.
Adrenergic/muscarinic autoimmunity may represent a biological mechanism distinct from structural brain atrophy in ME/CFS.
Remaining Questions
Do these autoantibody-related network changes correlate with specific clinical symptoms or disease severity in ME/CFS patients?
Are these autoantibodies present in all ME/CFS patients, or only a subset, and what factors determine who develops them?
What is the temporal relationship between autoantibody development and brain network changes—do antibodies cause the changes or vice versa?
What This Study Does Not Prove
This study demonstrates correlation, not causation—it does not prove these antibodies cause the brain changes observed. The findings are limited to local network properties in specific brain regions and do not establish whether these antibodies are universal in ME/CFS, affect clinical severity, or represent a primary pathogenic mechanism versus a secondary response.
Tags
Biomarker:AutoantibodiesNeuroimaging
Method Flag:No ControlsSmall SampleExploratory Only